To characterize the T-cell surface molecules involved in regulation of T-cell interleukin 2 (IL-2) responses, we established several monoclonal antibodies (mAbs) that inhibit IL-2 responses of freshly isolated CD8+ T cells and the IL-2-dependent cell line CTLL-2. Here we show that two inhibitory mAbs are directed against Lyt-2 (CD8a). In fact, all anti-Lyt-2 mAbs tested were able to inhibit the IL-2 response of the Lyt-2-and L3T4-dericient cell line HT-2 after transfection with a Lyt-2 cDNA clone. Similarly, anti-L3T4 mAbs inhibited the IL-2 response of CD4-transfected HT-2 cells. These inhibitory effects of anti-CD4 and anti-CD8 mAbs occur on normal T lymphocytes, since they also were observed with CD4+ and CD8+ T-cell blasts, and are specific for IL-2 responses, since IL-4 responses of CD4-and CD8-transfected HT-2 cells were not affected by the anti-CD4 and anti-CD8 mAbs. The inhibitory effects of anti-CD4 or anti-CD8 mAbs could not be explained by interference with IL-2 binding and depended on CD4 and CD8 crosslinking, because F(ab')2 or Fab plus crosslinking second antibody, but not Fab alone, were effective. A mutant Lyt-2 molecule lacking the cytoplasmic region that mediates p56kk binding could not mediate the inhibitory effect upon crosslinking. These results suggest that CD4 and CD8 mediate negative regulation of T-cell IL-2 responses via cytoplasmically associated p56kk.
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Interleukin 2 (IL-2) plays a central role in regulating immune responses (1) . IL-2-induced activation and differentiation signals are mediated by specific receptors on the cell surface. The IL-2 receptor (IL-2R) is composed of two polypeptides, p55 IL-2Ra and p75 IL-2RB. p55 or p75 alone constitute lowor intermediate-affinity receptor, respectively, but only the latter is functional in mediating signals. The combination of both subunits constitutes the functional high-affinity IL-2R (2) (3) (4) (5) (6) . cDNA transfection studies revealed that p55 and p75 were sufficient for reconstituting functional high-affinity IL2Rs on hematopoietic cell lines, but not on nonhematopoietic cell lines (7) (8) (9) (10) (11) (12) (13) . Similarly, p75 alone reconstituted the functional intermediate-affinity receptor only on hematopoietic cell lines (7, 12) . These results suggest that other hematopoietic components in addition to p55 and p75 are required for constitution of the functional IL-2R. In this respect, candidates for IL-2R-associated molecules have been reported (14) (15) (16) (17) . To re- spectively. Anti-Lyt-2.2 and anti-Lyt-2.1 (allotypic antiLyt-2 mAbs) were gifts from Meiji Milk Product (Tokyo). Anti-Lyt-3.2 and anti-Lyt-3.1 (HO-3.1) (allotypic anti-Lyt-3 mAbs) were kindly provided by E. Nakayama (Nagasaki University). F(ab')2 and Fab fragments of the mAbs were prepared as described (24) .
Immunizations and Production of mAbs. Adult SD rats (Sankyo Labo Service, Tokyo) were primed with an intradermal injection of 107 T-cell blasts [prepared by culturing BALB/c spleen cells with Con A (5 ,ug/ml) for 2 days] in complete Freund's adjuvant, followed by a booster injection, 10 days later, containing the same number of T-cell blasts in incomplete Freund's adjuvant, and i.p. injection of T-cell blasts in phosphate-buffered saline three times per week. After 10 days, antisera were collected and antibody activities against T-cell blasts were estimated by immunofluorescence. Animals developing a high titer of antibody were given a final i.p. injection of T-cell blasts (2 x 107). Immune splenocytes were prepared 3 days later and fused with P3X63Ag8-653 murine myeloma cells (25) . We screened for antibodies that inhibited IL-2 induction of anti-CD3-redirected cytotoxic activity in mouse spleen T cells as described below. mAbs 1C7-3, 2F4, 5D7-1, 5D9-2, and 5H10-1 were selected for their strong inhibitory effects and cloned by limiting dilution.
Cytotoxicity Assay. Spleen cells from BALB/c mice were cultured with recombinant human IL-2 (1000 units/ml) in the presence of the indicated mAb (10 ,ug/ml) with or without PC61 (10 ,ug/ml). After 2 days, the cells were harvested and their cytotoxic activity against Fc,, receptor-bearing P815 cells in the presence of anti-CD3 mAb (0.1 ,ug/ml) was tested in a standard 4-hr 5lCr-release assay. The effector/target cell Abbreviations: IL, interleukin; IL-2R, IL-2 receptor; mAb, monoclonal antibody. 1To whom reprint requests should be addressed.
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Proliferative Response of IL-2-and IL-4-Dependent Cell Lines. IL-2/IL-4-dependent cell lines were first deprived of IL-2 for >2 hr in complete medium. They were cultured at 370C for 24 hr in complete medium containing serially diluted IL-2 or IL-4 in the presence or absence of the mAbs (10 ,zg/ml) with or without PC61 (10 ,ug/ml). Proliferation was measured by incorporation of [3H]thymidine (1 ,tCi per well; 1 Ci = 37 GBq) during the last 4 hr of the culture.
Proliferative responses of CD81 or CD4+ T-cell blasts, which were induced from CD8+ and CD4+ spleen cells by culturing with phorbol 12-myristate 13-acetate (10 ng/ml), ionomycin (500 ng/ml), and recombinant human IL-2 (50 units/ml) for 5 days, were tested in a similar way.
Immunoprecipitation. Surface radioiodination of BALB/c thymocytes and immunoprecipitation were performed as described (27) .
CD4 and CD8 Expression Vectors and Transfection. The expression constructs containing of the full-length wild-type Lyt-2 cDNA or the mutant cDNA whose cytoplasmic region was truncated (Lyt-2-107A4) were prepared as described (28) . The expression construct containing the full-length L3T4 (pSFSVn-LC7) (29) was kindly provided by J. Parnes (Stanford University). HT-2 cells were transfected with those constructs by electroporation (30) . Selection with G418 (1 mg/ml) was started 48 hr after transfection. G418-resistant cells expressing a high level of Lyt-2 or L3T4 on the surface were isolated by fluorescence-activated cell sorting.
IL-2 Binding Assay. IL-2 binding and Scatchard analysis were done as described (11) .
Immunoprecipitation and Immunoblotting with Anti-p56ck Antibody. These procedures were performed as described (28) .
RESULTS
Establishment and Characterization of mAbs That Inhibit IL-2 Responses of Murine T Cells. We first tried to establish a mAb inhibiting IL-2 response of an IL-2-dependent cell line, HT-2, but the resulting mAbs were found to be directed to p55 IL-2Ra, probably due to its extremely high expression on HT-2. Based on our previous observation in human systems that cytotoxic activation ofperipheral blood CD8+ T cells is mediated solely by p75 IL-2Rj (31), we next screened for mAbs inhibiting the induction by IL-2 of cytotoxic activity of mouse splenic T cells in an anti-CD3-redirected cytotoxicity assay. We selected five mAbs (1C7-3, 2F4, 5D7-1, 5D9-2, 5H10-1) that did not inhibit the anti-CD3-redirected cytotoxicity significantly; control anti-Thy-1 mAb exhibited no inhibitory effect, excluding the possibility that the mAbs simply compete with anti-CD3 mAb for Fc receptor binding to the target cells (data not shown). In addition, these mAbs alone could partially inhibit the IL-2 response of the IL-2-dependent cell line CTLL-2, as well as cytotoxic induction of splenic T cells, and acted synergistically with an anti-p55 IL-2Ra mAb (PC61) in both systems (data not shown). Among these five mAbs, two (5D9-2 and 5H10-1) reacted weakly with CTLL-2 and very strongly with the majority of thymocytes and a subset of spleen cells as estimated by indirect immunofluorescence and flow cytometry. The antigen molecules on thymocytes recognized by these two mAbs were two disulfide-linked heterodimers composed of 38-and 30-kDa subunits or 35-and 30-kDa subunits, as estimated by immunoprecipitation and SDS/ PAGE (data not shown). The distribution and biochemical characteristics of the antigen recognized by 5D9-2 and 5H10-1 were reminiscent of murine CD8. Therefore, we compared the apparent molecular mass of the antigen immunoprecipitated by 5D9-2 and 5H10-1 with that of the CD8 molecule immunoprecipitated by an anti-Lyt-2 mAb, 53-6.72. These appeared to be identical. In sequential immunoprecipitation studies, preclearing of CD8 from a thymocyte lysate with the anti-Lyt-2 mAb completely depleted the antigen reactive with 5D9-2 and 5H10-1, and vice versa (data not shown). In addition, 5D9-2 and 5H10-1 competed with fluorescein-labeled 53-6.72 for binding to thymocytes as estimated by flow cytometry. Based on these data, we concluded that 5D9-2 and 5H10-1, which inhibited IL-2 responses, are directed to the Lyt-2 (CD8a) molecule. To determine whether the inhibitory effect on IL-2 response is unique for 5H9-2 and 5H10-1, or a general property of anti-CD8 mAbs, we used a panel of anti-Lyt-2 and anti-Lyt-3 (CD8f3) mAbs. All antiLyt-2 mAbs tested significantly inhibited the IL-2 response of CTLL-2, while this effect was not observed with irrelevant allotypic anti-Lyt-2.1 and anti-Lyt-3.1 mAbs (Fig. 1 ). An anti-Lyt-3.2 mAb did react with CTLL-2 to a similar extent as an anti-Lyt-2.2 mAb, as estimated by flow cytometry, but it did not inhibit the IL-2 response. These results indicate that the inhibitory effect on the IL-2 response is a general property of anti-Lyt-2 mAbs but not of anti-Lyt-3 mAbs.
Inhibitory Effects of Anti-Lyt-2 and Anti-L3T4 mAbs on IL-2 and IL-4 Responses of CD4-or CDga-Transfected HT-2 Cells. To further clarify the inhibitory effect of anti-Lyt-2 mAb on IL-2 responses, we introduced Lyt-2 into an IL-2-dependent cell line, HT-2, by cDNA transfection. HT-2 originally did not express CD8 or CD4 as determined by flow cytometry and Northern blot analysis (data not shown). HT-2 transfectants expressing high levels of Lyt-2 were isolated by fluorescence-activated cell sorting, and the effect of antiLyt-2 mAbs on the IL-2 response was examined (Fig. 2) . IL-2 response of the CD8a (Lyt-2) transfectant, but not that of the original HT-2 cells, was inhibited by 53-6.72 in a dosedependent manner. Similar effects were observed with 5D9-2 and 5H10-1 (data not shown). We also established a CD4 (L3T4)-transfected HT-2 cell line, and observed that its IL-2 response was inhibited to a higher extent by an anti-CD4 mAb (GK1.5) (Fig. 2) , indicating that CD4 is also involved in regulation of IL-2 responses. In contrast, control anti-Thy-1 mAb did not inhibit the IL-2 responses of these transfectants (data not shown).
In addition to IL-2, HT-2 can also respond to IL4. In contrast to the IL-2 response, however, the IL-4 response of the CD8a-or CD4-transfected HT-2 was not affected by anti-Lyt-2 or anti-L3T4 mAbs (Fig. 2) , indicating that the inhibitory effects were specific for IL-2 responses.
The inhibitory effects ofanti-Lyt-2 and anti-L3T4 mAbs on IL-2 response of the CD8a-or CD4-transfected HT-2 cells were dependent on the extent of CD8 or CD4 crosslinking. More extensive crosslinking using anti-rat immunoglobulin augmented the inhibitory effects of anti-Lyt-2 and anti-L3T4 mAbs (data not shown). Divalent F(ab')2 fragments were equally effective as intact mAbs, but monovalent Fab frag- ments were inhibitory only after crosslinking by anti-rat immunoglobulin (Fig. 3) .
To determine whether the inhibitory effects of anti-CD8 and anti-CD4 mAbs on IL-2 responses of IL-2-dependent T-cell clones could be generated on normal T cells, we prepared CD8+ and CD4+ T-cell blasts from spleen cells by isolating each population by fluorescence-activated cell sorting and activated them with phorbol ester and ionomycin. Anti-Lyt-2 and anti-L3T4 mAbs also significantly inhibited the IL-2 response of CD8+ and CD4+ T cell blasts, respectively (Fig. 4) . These results suggest that crosslinking of CD4 as well as CD8 leads to a specific down-regulation of IL-2 responses.
Involvement of Lyt-2-Associated p56Ick in Negative Regulation of IL-2 Responses. Anti-Lyt-2 and anti-L3T4 mAbs used above did not affect the binding of IL-2 to the CD8a-or CD4-transfected HT-2 cells as estimated by Scatchard analysis (data not shown). Therefore, inhibitory effects of these mAbs on IL-2 responses were likely to be directed to the signal-transduction pathway following binding of IL-2 to its receptor. IL-2R-mediated signal transduction has been reported to involve tyrosine phosphorylation (32) (33) (34) (35) , while CD4-and CD8-mediated signals have been supposed to be mediated by the protein-tyrosine kinase p561ck, which associates with the cytoplasmic portion of these molecules (36- 38). Therefore, it was feasible to test the involvement of p56lck in the inhibitory mechanisms. We introduced the cDNA encoding a mutant Lyt-2 molecule (Lyt-2-107A4) whose cytoplasmic portion was replaced with 8 nonsense amino acids instead of 28 amino acid residues ofthe wild-type Lyt-2 and, therefore, is unable to bind to p56lck (28) . The mutant Lyt-2 molecule was expressed on HT-2 cells at a level similar to that of the transfected wild-type Lyt-2 (data not shown). The wild-type, but not the mutant, Lyt-2 coprecipitated p56Ick as shown by immunoblotting of the anti-Lyt-2 immunoprecipitates with anti-p561ck antibody (Fig. 5) . L3T4 coprecipitated more p56Ick than wild-type Lyt-2, as previously reported (37) . By densitometry, 30%, 10%1, and <0.1% of total cellular p56Ick was associated with L3T4, wild-type Lyt-2, and mutant Lyt-2, respectively, in each transfectant. In contrast to the wild-type Lyt-2 transfectant, IL-2 as well as IL-4 responses of the mutant Lyt-2 transfectant were not inhibited by anti-Lyt-2 mAb (Fig. 6) . Therefore, the inhibitory effect of CD4 and CD8 crosslinking on IL-2 responses appears to be correlated strongly with the amount of p56lck associated with these molecules, suggesting the involvement ofp56Ick in the negative regulation of IL-2 responses resulting from CD4 and CD8 crosslinking. DISCUSSION Molecular cloning of p55 and p75 components of the IL-2R has enabled reconstitution studies to be performed by cDNA transfection (7) (8) (9) (10) (11) (12) (13) . They revealed that molecules other than p55 and p75 may be required for signal transduction via IL-2R. Several candidate molecules associating with the IL-2R have been reported (14) (15) (16) (17) . However, their functional properties have not been clarified. To characterize molecules involved in regulation of IL-2 responses, we established several mAbs that inhibit IL-2 responses of murine T cells. Unexpectedly, some of them were directed to the CD8a (Lyt-2) molecule. In addition, all anti-Lyt-2 and anti-L3T4 mAbs tested could inhibit IL-2 responses of splenic T-cell blasts, as well as those of the IL-2-dependent cell line CTLL-2 and CD8-or CD4-transfected HT-2 cells. However, these mAbs could not inhibit IL-4 responses of CD4-or CD8-transfected HT-2 cells, indicating that the inhibitory effects on IL-2 responses are not due to nonspecific inhibition of cell growth. Moreover, anti-Lyt-2 and anti-L3T4 mAbs did not affect the binding of IL-2 to Lyt-2-or L3T4-transfected HT-2 cells, suggesting that the inhibitory effect involves the signal transduction cascade via IL-2R.
IL-2 stimulation can lead to tyrosine phosphorylation of several substrates, including the p75 IL-2Rf3 chain itself (32) (33) (34) (35) . In addition, IL-2 responses can be inhibited by protein-tyrosine kinase inhibitors (39) . These reports suggest that protein-tyrosine kinases might be involved in the signaltransduction cascade via IL-2R, especially since neither p75 nor p55 has a tyrosine kinase domain (7). Hatakeyama et al. (40) reported that a lymphocyte-specific tyrosine kinase, p561ck, is physically associated with p75 IL-2Rf3 and that its kinase activity was promoted by IL-2 binding. Horak et al. (41) reported a similar increase of p561ck kinase activity after IL-2 stimulation of IL-2-dependent T-cell lines. These results suggest that p561ck associated with p75 may have a role in regulating IL-2R-mediated signal transduction. On the other hand, p56ck was first demonstrated to be associated with the cytoplasmic domains of CD8a and CD4 (36) (37) (38) . CD4 or CD8 crosslinking by anti-CD4 or anti-CD8 mAb promoted the kinase activity only of p561ck that associated with CD4 or CD8. Therefore, our present observation that CD4 or CD8 crosslinking down-regulates IL-2 responses via associated p5o6ck suggests a direct physical linkage between p75 IL-2Rf and CD4 or CD8a via the same p56ock molecule, although it is also possible that the inhibition may reflect an indirect mechanism, following some signal-transduction event resulting from crosslinking CD4 or CD8. This notion is consistent with the fact that CD8a or CD4 and p75 IL-2Rf bind to distinct sites on p56lck (40) . Further biochemical studies will be needed to test this possibility. However, p561ck is not always required for IL-2R-mediated signal transduction, because the growth of some cell lines lacking p5ock can be promoted by IL-2 after introduction of p75 (11, 40) . Moreover, a deletion mutant of p75 that cannot bind p561ck can work as a functional receptor (7, 40) . Therefore, p561ck appears to be not obligatory but regulatory for IL-2 responses, as demonstrated by our present study.
Crosslinking of CD4 by anti-CD4 mAb prior to T-cell receptor crosslinking can lead to T-cell unresponsiveness due to the induction of apoptosis (42) , and in vivo administration of anti-CD4 mAb can lead to allograft tolerance by inducing clonal anergy (43) . Although the molecular mechanisms for The physiological consequences of our present observations remain to be determined. CD4 and CD8 can bind directly to class II or class I major histocompatibility complex molecules, respectively, independently of the T-cell receptor (44) . Although their binding affinity appears to be so weak that the binding between CD4+ cells and class IIpositive cells could be observed only when these molecules were greatly overexpressed, such a weak interaction would be facilitated in the context of a T cell that is already binding to another cell via other antigen-independent adhesion molecules such as LFA-1 and CD2. Therefore, our results suggest that crosslinking of CD4 or CD8 by interaction with self class II or class I molecules might lead to suppression of T-cell IL-2 responsiveness. This may contribute to the inhibition of bystander T-cell activation by IL-2 produced by antigen-speciflic T cells. Such a mechanism inhibiting bystander activation would be particularly needed to direct CD8+ T cells to antigen-specific activation, since they constitutively express p75 IL-2R( and can respond to IL-2 without antigen stimulation (31) .
Another possibility is suggested by the observation that CD4 or CD8 crosslinking down-regulates IL-2 but not IL-4 responsiveness. It was reported that IL-4 inhibited the IL-2 induction of lymphokine-activated killer (LAK) activity but not antigen-specific cytotoxic activity in CD8+ T cells (45) . In the present study, CD4 or CD8 crosslinking affected IL-2 responses but not IL-4 responses. Crosslinking of CD8 on preactivated cytotoxic T cells by self class I would downregulate their responsiveness to higher doses of IL-2, which promotes broad LAK activity. Since only IL-2 responses were inhibited, crosslinking of CD8 confers preferential reactivity to IL-4, which augments antigen-specific cytotoxic T-cell activity. Therefore, CD4 or CD8 crosslinking by self major histocompatibility molecules may help preserve the antigen specificity of preactivated T cells by preventing the acquisition of a broad reactivity.
We have characterized the functional properties of two anti-Lyt-2 mAbs among five mAbs inhibiting IL-2 responses. In preliminary work, the antigens recognized by the other three mAbs were found to be expressed on several types of cytokine-responsive cell lines and could inhibit their responses to various cytokines, including IL-3 and IL-4 as well as IL-2. The p75 IL-2R/3 chain and the IL-3 and IL-4 receptors have been shown to belong to the same cytokine receptor family based on structural similarities (46) . Further analyses of mAbs that broadly affect cytokine responses might help elucidate the common signaling mechanisms shared by these receptors.
